Remove FDA Remove Immunization Remove Labelling
article thumbnail

Merck’s Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise

Fierce Pharma

Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer.

FDA 131
article thumbnail

FDA declines Eli Lilly’s bowel disease drug over manufacturing issues

Pharmafile

Pharma giant Eli Lilly’s Biologic Licence Application (BLA) for its bowel disease drug has been declined by the FDA over concerns about the proposed manufacturing of the drug. However, concerns weren’t expressed over the clinical data package, safety or label for the medicine.

FDA 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Immunocore claims first-ever FDA approval for TCR cancer therapy

pharmaphorum

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The post Immunocore claims first-ever FDA approval for TCR cancer therapy appeared first on.

FDA 124
article thumbnail

FDA adds warning of rare neurological side effect to J&J COVID jab

pharmaphorum

The FDA has added a new warning on the Johnson & Johnson COVID-19 vaccine, saying the shot has been linked to a serious but rare side effect – Guillain-Barré syndrome – that can cause muscle weakness. J&J requested the change to the label, which was confirmed in a letter to its Janssen Biotech subsidiary from the FDA yesterday.

FDA 98
article thumbnail

FDA accepts to review ImmunityBio’s BLA for bladder cancer treatment

Pharmaceutical Technology

The Food and Drug Administration (FDA) has acc epted to review ImmunityBio’s Biologics License Application (BLA) for N-803 to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients with or without Ta or T1 disease.

FDA 105
article thumbnail

EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejection

pharmaphorum

Sanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) were dashed by the FDA, but new phase 3 data keep the drugmaker on track for a resubmission before year-end. At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs.

FDA 96
article thumbnail

ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

pharmaphorum

Kymriah (tisagenlecleucel) was approved for relapsed/refractory ALL in 2017, but its label covers use in children and young adults aged up to 25, who account for the bulk of cases of the blood cancer. It was filed for the adult ALL indication in the US in April, and has a priority review from the FDA, with a verdict due in October.

FDA 105